GSA Capital Partners LLP Has $437,000 Holdings in Repligen Co. (RGEN)
GSA Capital Partners LLP grew its stake in Repligen Co. (NASDAQ:RGEN) by 105.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,277 shares of the biotechnology company’s stock after buying an additional 4,244 shares during the period. GSA Capital Partners LLP’s holdings in Repligen were worth $437,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. First Hawaiian Bank acquired a new stake in shares of Repligen in the fourth quarter worth about $28,000. Enlightenment Research LLC acquired a new stake in shares of Repligen in the fourth quarter worth about $42,000. Parallel Advisors LLC lifted its position in shares of Repligen by 485.1% in the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock worth $66,000 after buying an additional 1,043 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Repligen in the fourth quarter worth about $110,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Repligen in the third quarter worth about $116,000. 90.66% of the stock is owned by institutional investors.
NASDAQ RGEN opened at $60.13 on Friday. Repligen Co. has a twelve month low of $34.05 and a twelve month high of $70.50. The stock has a market cap of $2.64 billion, a P/E ratio of 82.37, a price-to-earnings-growth ratio of 4.07 and a beta of 1.09.
Several research firms recently weighed in on RGEN. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a research report on Thursday, November 29th. CL King raised Repligen from a “neutral” rating to a “buy” rating in a research report on Monday, December 17th. They noted that the move was a valuation call. Finally, BidaskClub cut Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $59.20.
In other Repligen news, VP Ralf Kuriyel sold 2,240 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $58.53, for a total value of $131,107.20. Following the completion of the transaction, the vice president now owns 21,043 shares of the company’s stock, valued at approximately $1,231,646.79. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Jon Snodgres sold 1,875 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $58.88, for a total value of $110,400.00. Following the completion of the transaction, the chief financial officer now directly owns 26,821 shares of the company’s stock, valued at approximately $1,579,220.48. The disclosure for this sale can be found here. Insiders have sold a total of 27,731 shares of company stock valued at $1,625,768 in the last three months. 1.40% of the stock is owned by insiders.
WARNING: “GSA Capital Partners LLP Has $437,000 Holdings in Repligen Co. (RGEN)” was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2019/03/16/gsa-capital-partners-llp-has-437000-holdings-in-repligen-co-rgen.html.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: Earnings Reports
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.